Literature DB >> 32097844

Sleep disturbance and atopic dermatitis: A bidirectional relationship?

E M S Xerfan1, J Tomimori2, M L Andersen3, S Tufik3, A S Facina4.   

Abstract

Atopic dermatitis (AD) is one of the most common pediatric dermatologic disorders and is associated with an increased risk of recurrent bacterial and viral cutaneous infections, such as impetigo, the most common bacterial infection in children. AD may impair patient quality of life in a number of ways, one of which is its impact on sleep. The way that the condition affects sleep has not yet been fully elucidated; it is clear that the symptoms of the disease such as pruritus and scratching can affect sleep but other factors, such as changes in the immunological system related to the disease can also have an effect. We argue that this relationship may be bi-directional, with changes to the skin barrier (barrier dysfunction, alterations in its microbiome and oxidative stress) and immunological function caused by the condition impairing sleep and leading to imbalanced inflammatory pathways that exacerbate AD and other associated conditions such as impetigo. We highlight the need for further studies to investigate this correlation between AD and sleep to make the role of this relationship clearer.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID: 32097844     DOI: 10.1016/j.mehy.2020.109637

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  3 in total

Review 1.  Interleukin-31 as a Clinical Target for Pruritus Treatment.

Authors:  Kenji Kabashima; Hiroyuki Irie
Journal:  Front Med (Lausanne)       Date:  2021-02-12

Review 2.  Psychologic interventions in patients with the chronic dermatologic itch in atopic dermatitis and psoriasis: A step forward with family constellations seminars.

Authors:  Szergej Capec; Martin Petrek; Gabriella Capec; Roman Yaremkevych; Yuriy Andrashko
Journal:  Front Med (Lausanne)       Date:  2022-08-12

3.  Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies.

Authors:  K Kabashima; T Matsumura; H Komazaki; M Kawashima
Journal:  Br J Dermatol       Date:  2021-12-21       Impact factor: 11.113

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.